Lv2
110 积分 2024-12-03 加入
Ensifentrine for COPD
1年前
已完结
Ensifentrine Plus a Long-Acting Muscarinic Antagonist in COPD: A Trifunctional Dual Bronchodilation Perspective
1年前
已完结
Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine Reduces Exacerbation Rate and Risk in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
1年前
已完结
Effect of ensifentrine on dyspnea in patients with moderate-to-severe chronic obstructive pulmonary disease: pooled analysis of the ENHANCE trials
1年前
已完结
Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine Reduces Exacerbation Rate and Risk in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
1年前
已完结
Clinical effectiveness of cefoperazone-sulbactam vs. piperacillin-tazobactam for the treatment of pneumonia in elderly patients
1年前
已完结
Contemporary Use of β‐Blockers in Heart Failure Patients With and Without Atrial Fibrillation: A Nationwide Database Analysis
1年前
已完结
Beta‐blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction
1年前
已完结
PI3K/Akt-Nrf2 and Anti-Inflammation Effect of Macrolides in Chronic Obstructive Pulmonary Disease
1年前
已完结
Benefit–harm analysis of azithromycin for the prevention of acute exacerbations of chronic obstructive pulmonary disease
1年前
已完结
皖公网安备34019202002308
